| 6800 |
Introduction to 100 Days Campaign |
18/10/2024 |
|
| 6804 |
Roles and Responsibilities of CHO under the 100 Days Campaign |
18/10/2024 |
|
| 6820 |
Preparation for the 100 Days Campaign- Team Members |
18/10/2024 |
|
| 861 |
System for TB Elimination in Private Sector [STEPS] |
20/10/2024 |
Partnerships and Multisectoral Engagement |
| 862 |
Patient Provider Support Agency [PPSA] |
20/10/2024 |
Partnerships and Multisectoral Engagement |
| 5 |
Advocacy Communication and Social Mobilisation [ACSM] |
20/10/2024 |
Advocacy communication and social mobilization |
| 1088 |
Methods for Pharmacovigilance Activity Reporting |
20/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1317 |
Universal Drug-susceptibility Testing [UDST] for TB |
20/10/2024 |
Laboratory services and management |
| 1416 |
Polymerase Chain Reaction [PCR] Technology for M.TB |
21/10/2024 |
Laboratory services and management |
| 1647 |
NTEP Performance Indicator - Percentage of TB Notified Patients with Universal Drug Susceptibility Testing [UDST] Done |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1653 |
NTEP Performance Indicator – Percentage Of Multidrug-resistant [MDR]/ Rifampicin-resistant [RR] Patients Initiated on Treatment Out of Totally Diagnosed |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1644 |
Root Cause Analysis [RCA] for Low Performance in Percentage of Target TB Notification Achieved |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1648 |
RCA for low performance of Percentage of TB Notified Cases with Universal Drug Susceptibility Testing Done |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1650 |
RCA for Low Performance - Suggested Solutions - Case Studies along 4 |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1652 |
RCA for low performance of Percentage of Eligible Beneficiaries Paid under Ni-kshay Poshan Yojana |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1656 |
RCA for low performance of Percentage Expenditure Against Approved Record of Proceedings [ROP] |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1660 |
RCA for low performance in in percentage of PLHIV given IPT against Total Eligible |
21/10/2024 |
Surveillance, SM&E and Epidemiology |
| 1791 |
Treatment Regimen for NTM |
21/10/2024 |
DR-TB and PMDT |
| 251 |
Screening and Diagnosis for DR-TB |
21/10/2024 |
DR-TB and PMDT |
| 207 |
Good Laboratory Practices (GLP) at a DMC |
21/10/2024 |
Laboratory services and management |
| 2189 |
Ziehl–Neelsen [ZN] Microscopy |
21/10/2024 |
Laboratory services and management |
| 2382 |
Types of monthly Patient Wise Boxes [PWB] |
21/10/2024 |
Procurement and supply chain management |
| 3195 |
Integrated Counseling and Testing Centre [ICTC] |
21/10/2024 |
TB Comorbidities and special conditions |
| 3196 |
Anti-Retroviral Therapy [ART] Centre |
21/10/2024 |
TB Comorbidities and special conditions |
| 3336 |
DR-TB Treatment Register |
21/10/2024 |
Ni-kshay, Information Systems and DBT |
| 3895 |
Susceptibility of MTB to p-Nitrobenzoic acid [PNB] |
21/10/2024 |
Laboratory services and management |
| 3916 |
Pyrazinamide [PZA] Susceptibility Testing |
21/10/2024 |
Laboratory services and management |
| 3948 |
Quality Assurance [QA] in TB C&DST Laboratories |
21/10/2024 |
Laboratory services and management |
| 3954 |
External QA for C&DST laboratories |
21/10/2024 |
Laboratory services and management |
| 4330 |
Isolated NTM and their sites of infection |
21/10/2024 |
DR-TB and PMDT |
